Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Synthalin SCHEMBL336302 | 0.97 | SMN1; SMN2 (0.67) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| SCHEMBL434733 | 0.97 | SMN1; SMN2 (0.67) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| Arcaine SCHEMBL29050632 | 0.97 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| SCHEMBL3069140 | 0.97 | SMN1; SMN2 (0.67) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| SCHEMBL1923256 | 0.97 | SMN1; SMN2 (0.67) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| SCHEMBL3072659 | 0.97 | SMN1; SMN2 (0.67) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| SCHEMBL10728151 | 0.97 | SMN1; SMN2 (0.67) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| Arcaine SCHEMBL11414566 | 0.97 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| SCHEMBL11882788 | 0.97 | SMN1; SMN2 (0.67) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL21715464 | 0.94 | SMN1; SMN2 (0.64) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819535-B2 | Composition and methods for regulating extracellular matrix accumulation | UNIVERSITY HEALTH NETWORK (CA) | 2023-11-21 | — | — | US | claimed |
| EP-2665739-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2013-11-27 | — | — | EP | claimed |
| US-20120322868-A1 | FOOD PRODUCTS, PREPARATION, AND THERAPEUTIC METHODS | SCHLOSS JOHN V (US) | 2012-12-20 | — | — | US | claimed |
| WO-2012100248-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2012-07-26 | — | — | WO | claimed |
| US-20120114670-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | UNIVERSITY OF ROCHESTER (US) | 2012-05-10 | — | — | US | claimed |
| US-20120082659-A1 | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-05 | — | — | US | claimed |
| US-8101744-B2 | Isolation and purification of nucleic acids with a solid phase | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| WO-2011103577-A1 | IMPROVED FOOD PRODUCTS, PREPARATION, AND THERAPEUTIC METHODS | SCHLOSS JOHN V (US) | 2011-08-25 | — | — | WO | claimed |
| EP-2196091-B1 | Synergistic combinations comprising at least one fungicide and a guanidine salt | STRAETMANS HIGH TAC GMBH (DE) | 2010-12-08 | — | — | EP | claimed |
| US-20100285001-A1 | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations | UNIVERSITY OF ROCHESTER (US) | 2010-11-11 | — | — | US | claimed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | claimed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | claimed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | claimed |
| EP-0797442-B1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRM (US) | 2003-05-21 | — | — | EP | claimed |
| JP-2002517462-A | — | — | 2002-06-18 | — | — | JP | claimed |
| WO-1999064041-A9 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1100519-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | Advanced Medicine, Inc. (US) | 2001-05-23 | — | — | EP | claimed |
| WO-1999064041-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1998010757-A9 | THE USE OF FUNCTIONAL N-METHYL-D-ASPARTATE ANTAGONISTS TO AMELIORATE OR PREVENT AMINOGLYCOSIDE-INDUCED OTOTOXICITY | — | 1998-07-23 | — | — | WO | claimed |
| WO-1998010757-A2 | THE USE OF FUNCTIONAL N-METHYL-D-ASPARTATE ANTAGONISTS TO AMELIORATE OR PREVENT AMINOGLYCOSIDE-INDUCED OTOTOXICITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322868-A1 | FOOD PRODUCTS, PREPARATION, AND THERAPEUTIC METHODS | SLC7A11, CTH, GNMT | MEN1 1244/4885KMT2A 2255/4885SMN1; SMN2 2921/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | MEN1 237/4885KMT2A 949/4885SMN1; SMN2 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.